Please assess the completion status of the following clinical trial:

Trial Title: Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Disease Characteristics~* The patient must be 18 years of age or older.~* The patient must have squamous cell carcinoma of the head and neck.~* The squamous cell carcinoma must be Ep-CAM positive.~* ECOG performance status of 0, 1, 2 or 3.~* 12 week life expectancy~Prior/Concurrent Therapy~* The patient must have received therapy for their primary disease (eg, surgery and/or radiotherapy, chemo-radiotherapy or chemotherapy).~* The patient must have been diagnosed with persistent or recurrent disease or a second primary tumour.~* The patient's disease must be refractory.~* There must be at least 2 weeks between the last dose of chemotherapy or radiotherapy and receiving study drug or 4 weeks between the last dose of an experimental drug and receiving study drug.~Patient Characteristics~* The patient must have adequate hepatic function \[alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × upper limit of normal (ULN) and bilirubin level ≤1.5 × ULN\].~* The patient must have adequate renal function (serum creatinine \< 1.5 × ULN).~* The patient must have the following hematological values: granulocytes ≥1500/μL, platelets ≥75 000/μL and hemoglobin \>8 g/dL.~* The patient must have prothrombin time and partial thromboplastin time within normal limits.~Other~• Women of childbearing potential and male patients must agree to use a highly effective contraceptive method.~Exclusion Criteria:~* The patient has clinically significant distant metastases.~* The patient is eligible to have surgical resection or radiotherapy, chemo-radiotherapy or chemotherapy.~* The patient has a nasopharyngeal tumour.~* The patient has AIDS, hepatitis C or hepatitis B.~* The patient has clinically significant renal or hepatic disease.~* Tumors are prone to bleeding.~* The patient is pregnant or lactating.~* The patient requires 'blood thinning' medications and can not safely discontinue the medication.~* The patient is currently enrolled in another clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Proxinium plus Best Supportive Care
- 2 (Type: NO_INTERVENTION): Best Supportive Care

Based on this trial design, predict the completion outcome and termination type (if applicable).